These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16871570)

  • 1. HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
    Morishima C; Morgan TR; Everhart JE; Wright EC; Shiffman ML; Everson GT; Lindsay KL; Lok AS; Bonkovsky HL; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Gretch DR;
    Hepatology; 2006 Aug; 44(2):360-7. PubMed ID: 16871570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.
    Morishima C; Morgan TR; Everhart JE; Wright EC; Apodaca MC; Gretch DR; Shiffman ML; Everson GT; Lindsay KL; Lee WM; Lok AS; Dienstag JL; Ghany MG; Curto TM;
    Hepatology; 2008 Nov; 48(5):1412-9. PubMed ID: 18816437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordance between HCV RNA assays for week 24 HCV RNA determination during pegylated interferon-α/ribavirin treatment for chronic hepatitis C.
    Roomer R; van Vuuren AJ; Schutten M; Heijens A; Janssen HL; de Knegt RJ
    Antivir Ther; 2011; 16(5):771-4. PubMed ID: 21817199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
    Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S
    J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of hepatitis C virus RNA detection by transcription-mediated amplification with negative polymerase chain reaction during therapy with peginterferon alpha and ribavirin.
    Kadam JS; Gonzalez SA; Ahmed F; Menezes A; Jacobson IM
    Dig Dis Sci; 2007 Oct; 52(10):2525-30. PubMed ID: 17406826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predicting sustained virological response in chronic hepatitis C patients treated with pegylated interferon and ribavirin using a novel highly sensitive Real-time detection PCR assay].
    Matsuura K; Tanaka Y; Takagi K; Hiramatsu K; Kani S; Gotoh T; Wakimoto Y; Joh T; Mizokami M
    Rinsho Byori; 2007 Nov; 55(11):983-8. PubMed ID: 18154028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve-week posttreatment follow-up to predict sustained virologic response for recurrent hepatitis C infection in liver recipients.
    Campos-Varela I; Castells L; Esteban JI; Bes M; Rodríguez-Frías F; Sapisochin G; Allende H; Charco R; Esteban R
    Transplantation; 2012 Feb; 93(4):450-3. PubMed ID: 22262129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
    Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
    J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Payan C; Pivert A; Morand P; Fafi-Kremer S; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F;
    Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
    Rivero-Juárez A; Mira JA; Pérez-Camacho I; Macías J; Camacho A; Neukam K; Torre-Cisneros J; Merchante N; Pineda JA; Rivero A;
    J Antimicrob Chemother; 2011 Jun; 66(6):1351-3. PubMed ID: 21415037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
    Halfon P; Pénaranda G; Bourlière M; Khiri H; Masseyeff MF; Ouzan D
    J Med Virol; 2006 Feb; 78(2):208-15. PubMed ID: 16372298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Usefulness of Defining Rapid Virological Response by a Very Sensitive Assay (TMA) during Treatment of HCV Genotype 2/3 Infection.
    Dalgard O; Martinot-Peignoux M; Verbaan H; Bjøro K; Ring-Larsen H; Marcellin P
    PLoS One; 2015; 10(8):e0120866. PubMed ID: 26317978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse.
    Gerotto M; Dal Pero F; Bortoletto G; Ferrari A; Pistis R; Sebastiani G; Fagiuoli S; Realdon S; Alberti A
    J Hepatol; 2006 Jan; 44(1):83-7. PubMed ID: 16271794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abbott RealTime hepatitis C virus (HCV) and Roche Cobas AmpliPrep/Cobas TaqMan HCV assays for prediction of sustained virological response to pegylated interferon and ribavirin in chronic hepatitis C patients.
    Matsuura K; Tanaka Y; Hasegawa I; Ohno T; Tokuda H; Kurbanov F; Sugauchi F; Nojiri S; Joh T; Mizokami M
    J Clin Microbiol; 2009 Feb; 47(2):385-9. PubMed ID: 19091819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of the transcription-mediated amplification assay.
    Ferraro D; Giglio M; Bonura C; Di Marco V; Mondelli MU; Craxì A; Di Stefano R
    J Viral Hepat; 2008 Jan; 15(1):66-70. PubMed ID: 18088247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.